Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 3/20 | 0.37 |
| ▸ | ADH1A | P07327 | 3/20 | 0.37 |
| ▸ | ADH7 | P40394 | 3/20 | 0.37 |
| ▸ | ADH1C | P00326 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | ADH4 | P08319 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28734863 | 0.86 | MEN1 (0.50) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL3085848 | 0.86 | MEN1 (0.50) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL10940490 | 0.85 | ADH1B (0.48) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL404646 | 0.84 | — | — | |
| SCHEMBL19140519 | 0.80 | ADH1B (0.38) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL24798076 | 0.79 | ADH1B (0.39) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL27302343 | 0.79 | ADH1B (0.39) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL24134647 | 0.78 | ADH1B (0.37) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL23251714 | 0.77 | ADH1B (0.37) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL24205319 | 0.77 | ADH1B (0.37) | ADH1BADH1AADH7ADH1CEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | NOVO NORDISK A/S (DK) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | ADAR, NCL, SSU72 | ADH1B 3992/4885ADH1A 3549/4885ADH7 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.